Zacks Investment Research downgraded shares of Krystal Biotech (NASDAQ:KRYS) from a hold rating to a sell rating in a report released on Wednesday morning, Zacks.com reports.
According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “
Several other research analysts have also recently commented on the stock. Goldman Sachs Group began coverage on shares of Krystal Biotech in a report on Tuesday, September 24th. They issued a neutral rating and a $60.00 target price for the company. Cowen reiterated a buy rating on shares of Krystal Biotech in a report on Thursday, August 15th. ValuEngine cut shares of Krystal Biotech from a buy rating to a hold rating in a report on Wednesday, October 2nd. William Blair reiterated a buy rating on shares of Krystal Biotech in a report on Wednesday, September 4th. Finally, Guggenheim set a $81.00 target price on shares of Krystal Biotech and gave the stock a buy rating in a report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. Krystal Biotech has a consensus rating of Buy and an average price target of $60.67.
Shares of KRYS traded up $1.22 during mid-day trading on Wednesday, hitting $37.41. The company’s stock had a trading volume of 132,814 shares, compared to its average volume of 211,999. The firm has a 50-day moving average price of $41.80 and a 200 day moving average price of $38.18. The stock has a market capitalization of $622.47 million, a price-to-earnings ratio of -38.57 and a beta of 1.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 49.80 and a quick ratio of 49.80. Krystal Biotech has a fifty-two week low of $14.70 and a fifty-two week high of $51.67.
Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). As a group, equities analysts anticipate that Krystal Biotech will post -1.47 EPS for the current fiscal year.
In related news, Director Daniel Janney sold 88,684 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $46.46, for a total transaction of $4,120,258.64. Following the completion of the sale, the director now directly owns 35,131 shares in the company, valued at $1,632,186.26. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 34.30% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. Magnetar Financial LLC acquired a new stake in shares of Krystal Biotech during the second quarter worth approximately $483,000. Orbimed Advisors LLC boosted its holdings in shares of Krystal Biotech by 984.3% during the second quarter. Orbimed Advisors LLC now owns 642,006 shares of the company’s stock worth $25,854,000 after purchasing an additional 582,796 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Krystal Biotech during the second quarter worth approximately $2,523,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Krystal Biotech by 204.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 927,079 shares of the company’s stock worth $37,333,000 after purchasing an additional 622,959 shares during the period. Finally, Citadel Advisors LLC boosted its holdings in shares of Krystal Biotech by 54.0% during the second quarter. Citadel Advisors LLC now owns 497,170 shares of the company’s stock worth $20,021,000 after purchasing an additional 174,296 shares during the period. Institutional investors and hedge funds own 56.40% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
Featured Article: Cost of Equity
Get a free copy of the Zacks research report on Krystal Biotech (KRYS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.